Welcome to chemicalbook!
010-86108875
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

Pazopanib-d6

Pazopanib-d6 Structure
  • ₹0
  • Product name: Pazopanib-d6
  • CAS: 1219592-01-4
  • MF: C21H23N7O2S
  • MW: 437.52
  • EINECS:
  • MDL Number:
  • Synonyms:Pazopanib-d6;2-methyl-5-[[4-[methyl-d3-[3-methyl-2-(methyl-d3)-2H-indazol-6-yl]amino]-2-pyrimidinyl]amino]-benzenesulfonamide;2H6]-Pazopanib;2-methyl-5-({4-[(2H?)methyl[2-(2H?)methyl-3-methyl-2H-indazol-6-yl]amino]pyrimidin-2-yl}amino)benzene-1-sulfonamide;D6-Pazopanib
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

storage temp. :Store at -20°C
solubility :DMF: 16 mg/ml; DMSO: 16 mg/ml
form :A solid
color :White to off-white

Safety Information

Symbol(GHS):
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
Precautionary statements:

Description

Pazopanib-d6 is intended for use as an internal standard for the quantification of pazopanib by GC- or LC-MS. Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay).1 It also inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional receptor tyrosine kinases. Pazopanib inhibits upregulation of the surface adhesion proteins ICAM-1 and VCAM-1 induced by VEGF in multiple myeloma cells cocultured with human umbilical vein endothelial cells (HUVECs) and decreases multiple myeloma cell adhesion to HUVECs.2 It also inhibits proliferation of multiple myeloma cells cocultured with HUVECs. Pazopanib (30 and 100 mg/kg) reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model. Formulations containing pazopanib have been used in the treatment of cancer.

Related product price